Kate Lomas

Peter Mac and Monash University scientists have, for the first time, filmed how key proteins in the “Hippo pathway” move and bind to DNA in real time, offering new insights into how this ancient signalling system controls cell growth, repair, and death — and how its disruption contributes to cancers like mesothelioma. Led by Professor Kieran Harvey and Dr Benjamin Kroeger, the study reveals how TEAD and YAP proteins regulate which genes cells produce. Two drugs targeting this pathway are already in first-in-human trials at Peter Mac, raising hopes for new treatments for mesothelioma and other hard-to-treat cancers. Read more about the research and access the full paper: https://lnkd.in/gFUQrc2w

230

8 Comments

The latest benefit-cost analysis of the Australian Cereal Rust Control Program (ACRCP) has calculated a $6.01 return for every $1 invested in Phase 4 of the program. The ACRCP was launched in 2002 as a collaborative research program with investment from GRDC and research partners, particularly the University of Sydney, CSIRO and the CIMMYT (International Maize and Wheat Improvement Center). Phase 4 took place between 2017 and 2023. A 2024 analysis by ACIL Allen found the present value of total benefits for Phase 4 was estimated at $263.95 million – with $127.81 million attributable to GRDC investments. Well done and thank you to all the great researchers, growers and others involved in this work! Read more https://bit.ly/4mexVDf

98

4 Comments

Dr Adrienne Grech from mRNA Victoria has returned from Sydney with fresh insights and valuable connections following the three-day A-RNA 2025 conference.   The conference brought together Australia's leading RNA researchers and industry experts, featuring cutting-edge research presentations and workshops that are shaping the future of RNA therapeutics.   BioNTech SE, a key Victorian Government partner, chaired the Commercialisation Workshop providing attendees access to global innovators and supporting the upskilling of the local ecosystem to improve translation of Australian research.     As a vital platform for advancing RNA research and innovation across Australia and the Asia-Pacific region, A-RNA 2025 provided an invaluable opportunity for cross-sector collaboration and knowledge exchange.   "The national RNA research landscape is very exciting, with great progress across human health and agricultural applications ," said Dr Grech.   These connections and insights are strengthening mRNA Victoria's mission to build Australia's mRNA ecosystem and drive breakthrough innovations in RNA therapeutics.   #ARNASYDNEY25 #mRNAVictoria #RNAResearch #RNATherapeutics #Biotechnology #Innovation #Australia #Networking

59

2 Comments

🔑 National PID strategies are key to driving ORCID adoption around the world. We are pleased that ORCID is featured in the new PID Action Plan by Australian Research Council (ARC), which will help the research community in Australia in a number of ways: 👉 increase the use of priority persistent identifiers 👉 reduce duplication of research 👉 improve researcher accountability and research reproducibility, and 👉 increase the quality of data available to ARC The PID Action Plan has five goals: Goal 1: ARC grants have a Digital Object Identifier (DOI) Goal 2: All Administering Organizations applying for an ARC grant have a Research Organization Registry (ROR) identifier Goal 3: All named personnel have an Open Researcher and Contributor ID (ORCID iD) and supply it during the establishment phase of ARC awarded grants Goal 4: ARC's Research Management System (RMS) ORCID integration writes back to ORCID Goal 5: ARC has a FAIR Data Policy Learn more ➡️ https://lnkd.in/gQqm_pBu

45

1 Comment

We’ve signed a Memorandum of Understanding with K-Bio Lab Hub, South Korea’s flagship biotech incubator, to establish a Melbourne launchpad within the Monash Technology Precinct. From 2025, the launchpad will support Korean biotech startups, with ambitions to grow to 30 companies by 2027. These ventures will focus on therapeutics nearing clinical trials and early-stage drug discovery, building new opportunities for joint research, clinical translation and commercialisation. We’re thrilled to reinforce Victoria’s reputation as a life sciences hub in the Asia-Pacific by serving as a leading global partner in innovation and research. https://lnkd.in/g37AGftP

97